β-Arrestin mediates the Frank–Starling mechanism of cardiac contractility

Significance The Frank–Starling law of the heart describes the heart’s ability to enhance contractility in response to increased cardiac filling. This property is fundamental to how humans maintain cardiovascular function in response to changes in circulating blood volume, and is regulated by enhanced calcium sensitivity of myofilaments with biomechanical stretch. The mechanism of how biomechanical stretch leads to changes in the myofilament calcium sensitivity remains poorly understood. Using genetic and pharmacologic approaches, we show that β-arrestin and the angiotensin II type I receptor act as crucial molecular regulators of the Frank–Starling law of the heart. This work identifies β-arrestins as important regulators of this fundamental principle of cardiac contractility. The Frank–Starling law of the heart is a physiological phenomenon that describes an intrinsic property of heart muscle in which increased cardiac filling leads to enhanced cardiac contractility. Identified more than a century ago, the Frank–Starling relationship is currently known to involve length-dependent enhancement of cardiac myofilament Ca2+ sensitivity. However, the upstream molecular events that link cellular stretch to the length-dependent myofilament Ca2+ sensitivity are poorly understood. Because the angiotensin II type 1 receptor (AT1R) and the multifunctional transducer protein β-arrestin have been shown to mediate mechanosensitive cellular signaling, we tested the hypothesis that these two proteins are involved in the Frank–Starling mechanism of the heart. Using invasive hemodynamics, we found that mice lacking β-arrestin 1, β-arrestin 2, or AT1R were unable to generate a Frank–Starling force in response to changes in cardiac volume. Although wild-type mice pretreated with the conventional AT1R blocker losartan were unable to enhance cardiac contractility with volume loading, treatment with a β-arrestin–biased AT1R ligand to selectively activate β-arrestin signaling preserved the Frank–Starling relationship. Importantly, in skinned muscle fiber preparations, we found markedly impaired length-dependent myofilament Ca2+ sensitivity in β-arrestin 1, β-arrestin 2, and AT1R knockout mice. Our data reveal β-arrestin 1, β-arrestin 2, and AT1R as key regulatory molecules in the Frank–Starling mechanism, which potentially can be targeted therapeutically with β-arrestin–biased AT1R ligands.

[1]  R. Lefkowitz,et al.  Independent β-Arrestin2 and Gq/Protein Kinase Cζ Pathways for ERK Stimulated by Angiotensin Type 1A Receptors in Vascular Smooth Muscle Cells Converge on Transactivation of the Epidermal Growth Factor Receptor* , 2009, Journal of Biological Chemistry.

[2]  G. Andersen,et al.  Alpha(1)-AR-induced positive inotropic response in heart is dependent on myosin light chain phosphorylation. , 2002, American journal of physiology. Heart and circulatory physiology.

[3]  J. Violin,et al.  The β-arrestin-biased ligand TRV120023 inhibits angiotensin II-induced cardiac hypertrophy while preserving enhanced myofilament response to calcium. , 2013, American journal of physiology. Heart and circulatory physiology.

[4]  B. Wolska,et al.  Correlations between alterations in length-dependent Ca2+ activation of cardiac myofilaments and the end-systolic pressure–volume relation , 2008, Journal of Muscle Research and Cell Motility.

[5]  B Buis,et al.  Continuous measurement of left ventricular volume in animals and humans by conductance catheter. , 1984, Circulation.

[6]  Ryan T. Strachan,et al.  Allosteric Modulation of β-Arrestin-biased Angiotensin II Type 1 Receptor Signaling by Membrane Stretch* , 2014, The Journal of Biological Chemistry.

[7]  Norio Fukuda,et al.  Titin/connectin-based modulation of the Frank-Starling mechanism of the heart , 2006, Journal of Muscle Research & Cell Motility.

[8]  Stephen H. Smith,et al.  Left Ventricular and Myocardial Function in Mice Expressing Constitutively Pseudophosphorylated Cardiac Troponin I , 2009, Circulation research.

[9]  K. Rakesh,et al.  β-Arrestin–Biased Agonism of the Angiotensin Receptor Induced by Mechanical Stress , 2010, Science Signaling.

[10]  K. McDonald,et al.  Protein kinase C depresses cardiac myocyte power output and attenuates myofilament responses induced by protein kinase A , 2012, Journal of Muscle Research and Cell Motility.

[11]  M. Rief,et al.  Structural insight into M-band assembly and mechanics from the titin-obscurin-like-1 complex , 2010, Proceedings of the National Academy of Sciences.

[12]  H. Cingolani,et al.  The Anrep effect requires transactivation of the epidermal growth factor receptor , 2010, The Journal of physiology.

[13]  J. V. Van Eyk,et al.  p21-Activated Kinase Increases the Calcium Sensitivity of Rat Triton-Skinned Cardiac Muscle Fiber Bundles via a Mechanism Potentially Involving Novel Phosphorylation of Troponin I , 2002, Circulation research.

[14]  S. Çakmak,et al.  Loss of hepatitis A virus antibodies after bone marrow transplantation , 2006, Bone Marrow Transplantation.

[15]  R. Solaro Mechanisms of the Frank-Starling law of the heart: the beat goes on. , 2007, Biophysical journal.

[16]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[17]  Naoto Yagi,et al.  Effects of sustained length-dependent activation on in situ cross-bridge dynamics in rat hearts. , 2007, Biophysical journal.

[18]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[19]  K. McDonald,et al.  Titin-mediated control of cardiac myofibrillar function. , 2014, Archives of biochemistry and biophysics.

[20]  H. Cingolani,et al.  Reverse Mode of the Na+-Ca2+ Exchange After Myocardial Stretch: Underlying Mechanism of the Slow Force Response , 2001, Circulation research.

[21]  P. D. de Tombe,et al.  Cardiac Troponin I Threonine 144: Role in Myofilament Length–Dependent Activation , 2007, Circulation research.

[22]  A. Hall,et al.  Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox , 2006, Circulation.

[23]  J. Kuo,et al.  Cardiac Troponin I Mutants , 1995, The Journal of Biological Chemistry.

[24]  Marion L Greaser,et al.  Vertical agarose gel electrophoresis and electroblotting of high‐molecular‐weight proteins , 2003, Electrophoresis.

[25]  G. von Anrep On the part played by the suprarenals in the normal vascular reactions of the body , 1912, The Journal of physiology.

[26]  J. Violin,et al.  Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. , 2007, The Journal of clinical investigation.

[27]  G. Hasenfuss,et al.  The effect of myosin light chain 2 dephosphorylation on Ca2+ -sensitivity of force is enhanced in failing human hearts. , 2003, Cardiovascular research.

[28]  J. Violin,et al.  β-Arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes , 2006, Proceedings of the National Academy of Sciences.

[29]  J. Violin,et al.  β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection , 2007 .

[30]  H. Cingolani,et al.  The Anrep effect: 100 years later. , 2013, American journal of physiology. Heart and circulatory physiology.

[31]  M. Mayr,et al.  Protein Kinase D Selectively Targets Cardiac Troponin I and Regulates Myofilament Ca2+ Sensitivity in Ventricular Myocytes , 2007, Circulation research.

[32]  Lisa Nguyen,et al.  Selectively Engaging β-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance , 2010, Journal of Pharmacology and Experimental Therapeutics.

[33]  A. Shah,et al.  Protection against endotoxemia‐induced contractile dysfunction in mice with cardiac‐specific expression of slow skeletal troponin I , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  D. Martyn,et al.  Cardiac length dependence of force and force redevelopment kinetics with altered cross-bridge cycling. , 2004, Biophysical journal.

[35]  W. Pyle,et al.  At the crossroads of myocardial signaling: the role of Z-discs in intracellular signaling and cardiac function. , 2004, Circulation research.

[36]  S. Sadayappan,et al.  PKC-betaII sensitizes cardiac myofilaments to Ca2+ by phosphorylating troponin I on threonine-144. , 2006, Journal of molecular and cellular cardiology.

[37]  D. Kass,et al.  Cardiac resynchronization sensitizes the sarcomere to calcium by reactivating GSK-3β. , 2014, The Journal of clinical investigation.

[38]  E. Homsher,et al.  Phosphorylation or Glutamic Acid Substitution at Protein Kinase C Sites on Cardiac Troponin I Differentially Depress Myofilament Tension and Shortening Velocity* , 2003, The Journal of Biological Chemistry.

[39]  I. Komuro,et al.  Conformational switch of angiotensin II type 1 receptor underlying mechanical stress‐induced activation , 2008, EMBO reports.

[40]  A. Katz,et al.  Ernest Henry Starling, His Predecessors, and the “Law of the Heart” , 2002, Circulation.

[41]  R. Lefkowitz,et al.  Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. , 2012, Annual review of pharmacology and toxicology.

[42]  I. Lauder,et al.  Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension , 2005, Journal of Human Hypertension.

[43]  R. Solaro,et al.  Calcium, thin filaments, and the integrative biology of cardiac contractility. , 2005, Annual review of physiology.

[44]  R. Moss,et al.  Protein kinase A–induced myofilament desensitization to Ca2+ as a result of phosphorylation of cardiac myosin–binding protein C , 2010, The Journal of general physiology.

[45]  R. Solaro,et al.  Use of 2‐D DIGE analysis reveals altered phosphorylation in a tropomyosin mutant (Glu54Lys) linked to dilated cardiomyopathy , 2008, Proteomics.

[46]  Keshava Rajagopal,et al.  Teaching old receptors new tricks: biasing seven-transmembrane receptors , 2010, Nature Reviews Drug Discovery.

[47]  D. Bers,et al.  A Critical Function for Ser-282 in Cardiac Myosin Binding Protein-C Phosphorylation and Cardiac Function , 2011, Circulation research.

[48]  E. Rozengurt,et al.  Rapid activation of the novel serine/threonine protein kinase, protein kinase D by phorbol esters, angiotensin II and PDGF‐BB in vascular smooth muscle cells , 1998, FEBS letters.

[49]  Dahua Zhang,et al.  Protein kinase C and A sites on troponin I regulate myofilament Ca2+ sensitivity and ATPase activity in the mouse myocardium , 2003, The Journal of physiology.

[50]  J. Violin,et al.  β-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury. , 2012, American journal of physiology. Heart and circulatory physiology.

[51]  J. Leiden,et al.  Attenuation of length dependence of calcium activation in myofilaments of transgenic mouse hearts expressing slow skeletal troponin I , 2000, The Journal of physiology.

[52]  R. Mamidi,et al.  Length-dependent changes in contractile dynamics are blunted due to cardiac myosin binding protein-C ablation , 2014, Front. Physiol..